New CEO at Gyros AB


Lars Eric Utterman takes over as acting CEO after Jan Würtz

Jan Würtz has worked diligently to implement the strategies set by the board during his years as CEO. A significant and growing market for Gyros’ products is now emerging. In the phase of change that lays ahead a CEO with a different profile is required.

Until a permanent CEO is assigned Lars Eric Utterman will serve as acting CEO.

Utterman has extensive experience in the Biotech and Life Science industry. In particular, his skills in the area of marketing and sales of capital equipment for life science research will be an important asset at Gyros.

Lars Eric Utterman is well renowned in the industry. His informal and enthusiastic way of involvement is known to bring energy into organisations and processes.

The board and the major investors are confident about Gyros’ technology and its employee’s ability to turn Gyros into a successful company.

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.